Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A carcinoma that arises from the pancreas showing both ductal and squamous differentiation. The squamous component should represent at least 30% of the malignant cellular infiltrate. The prognosis is usually worse than that of ductal adenocarcinoma.
Biomarker and diagnostic research for pancreatic adenosquamous carcinoma has been reported in the published literature.
6 clinical trials registered, 3 recruiting. Interventions under study include drug therapy, procedural interventions, other interventions, and biologic therapy. Pipeline includes 3 PHASE3, 2 PHASE2, 1 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06115499](https://clinicaltrials.gov/study/NCT06115499) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 6:56 PM UTC
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer |
PHASE2 |
Alliance for Clinical Trials in Oncology |
UNKNOWN |
[NCT04858334](https://clinicaltrials.gov/study/NCT04858334) | APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | PHASE2 | National Cancer Institute (NCI) | RECRUITING |
[NCT07491445](https://clinicaltrials.gov/study/NCT07491445) | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | PHASE3 | Revolution Medicines, Inc. | RECRUITING |
[NCT04340141](https://clinicaltrials.gov/study/NCT04340141) | Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer | PHASE3 | Alliance for Clinical Trials in Oncology | ACTIVE_NOT_RECRUITING |
[NCT04157127](https://clinicaltrials.gov/study/NCT04157127) | Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma | PHASE1 | Diakonos Oncology Corporation | RECRUITING |
50 publications have been identified in PubMed for pancreatic adenosquamous carcinoma. Research spans Case Report / Case Series (28%), Basic Science / Preclinical (22%), and Epidemiology / Natural History (18%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 14 | 28% |
Laboratory research | 11 | 22% |
Disease patterns and progression | 9 | 18% |
Testing and diagnosis research | 4 | 8% |
Research summaries | 4 | 8% |
Clinical study results | 4 | 8% |
Other research | 2 | 4% |
New treatment approaches | 2 | 4% |
Ramia JM (2026). [PMID: 42157261](https://pubmed.ncbi.nlm.nih.gov/42157261/). *World J Surg Oncol*. [Other]
Santos IR (2026). [PMID: 41520219](https://pubmed.ncbi.nlm.nih.gov/41520219/). *Vet Pathol*. [Basic Science / Preclinical]
Sasaki S (2026). [PMID: 41912788](https://pubmed.ncbi.nlm.nih.gov/41912788/). *Langenbecks Arch Surg*. [Epidemiology / Natural History]
Ramia JM (2026). [PMID: 41593271](https://pubmed.ncbi.nlm.nih.gov/41593271/). *Ann Surg Oncol*. [Clinical Trial Publication]
Chen X (2026). [PMID: 41337905](https://pubmed.ncbi.nlm.nih.gov/41337905/). *Eur J Cancer*. [Basic Science / Preclinical]
Ramia JM (2026). [PMID: 41712156](https://pubmed.ncbi.nlm.nih.gov/41712156/). *Ann Surg Oncol*. [Basic Science / Preclinical]
Xi W (2026). [PMID: 41983198](https://pubmed.ncbi.nlm.nih.gov/41983198/). *Hepatobiliary Surg Nutr*. [Case Report / Case Series]
Pan Z (2026). [PMID: 41978418](https://pubmed.ncbi.nlm.nih.gov/41978418/). *Beijing Da Xue Xue Bao Yi Xue Ban*. [Review / Meta-Analysis]
Huang Y (2026). [PMID: 41461591](https://pubmed.ncbi.nlm.nih.gov/41461591/). *Pancreatology*. [Epidemiology / Natural History]
Van den Bossche JL (2026). [PMID: 42242908](https://pubmed.ncbi.nlm.nih.gov/42242908/). *Gut*. [Basic Science / Preclinical]
AI-curated news mentioning pancreatic adenosquamous carcinoma
Updated Aug 14, 2026
New research highlights the clinical, genomic, and spatial transcriptomic characteristics of pancreatic adenosquamous carcinoma, suggesting the need for subtype-specific therapeutic strategies. This study may guide future treatment approaches for this rare cancer type.
A new case series highlights the complexities of adenosquamous carcinoma of the esophagus, a rare and aggressive form of cancer. This research contributes to the understanding of its clinical behavior and potential treatment challenges.
Recent research highlights futility in treatment approaches for adenosquamous pancreatic cancer, indicating a need for novel therapeutic strategies. This study underscores the challenges faced in managing this aggressive cancer subtype.